复宏汉霖:帕妥珠单抗生物类似药HLX11(抗HER2结构域II人源化单克隆抗体注射液)的上市许可申请(MAA)获欧洲药品管理局(EMA)受理

格隆汇
28 Mar

格隆汇3月28日丨复宏汉霖(02696.HK)公告,近日,公司自主研发的Perjeta®(帕妥珠单抗)生物类似药候选药HLX11(重组抗HER2结构域II人源化单克隆抗体注射液)("HLX11")的上市许可申请("MAA")获欧洲药品管理局("EMA")受理,本次申请涉及的适应症如下:(1)与曲妥珠单抗和化疗联合:用于HER2阳性、局部晚期、炎性或早期乳腺癌且具有高复发风险成人患者的新辅助治疗;...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10